Table 1.
Patient characteristics in the whole cohort and according to the absolute monocyte count (group A < 0.2 × 109/L, group B 0.2–0.4 × 109/L, group C > 0.4 × 109/L).
| Group A | Group B | Group C | p | |||
|---|---|---|---|---|---|---|
| All | AMC <0.2 × 109/L |
AMC 0.2–0.4 × 109/L |
AMC > 0.4 × 109/L | A vs. B | B vs. C | |
| WHO 2016, n (%) | 993 | 529 | 241 | 223 | ||
| MDS-SLD | 71 (7.2) | 38 (7.2) | 18 (7.5) | 15 (6.7) | ||
| MDS-MLD | 302 (30.4) | 157 (29.7) | 70 (29) | 75 (33.6) | ||
| MDS-RS-SLD | 46 (4.6) | 15 (2.8) | 17 (7.1) | 14 (6.3) | ||
| MDS-RS-MLD | 92 (9.3) | 37 (7) | 24 (10) | 31 (13.9) | ||
| MDS(del5q) | 115 (11.6) | 54 (10.2) | 46 (19.1) | 15 (6.7) | ||
| MDS-EB-1 | 162 (16.3) | 86 (16.3) | 34 (14.1) | 42 (18.8) | ||
| MDS-EB-2 | 194 (19.5) | 138 (26.1 | 29 (12) | 27 (12.1) | ||
| MDS-U | 11 (1.1) | 4 (0.8) | 3 (1.2) | 4 (1.8) | ||
| IPSS-R, n (%) | ||||||
| Very low | 54 (5.4) | 19 (3.6) | 18 (7.5) | 17 (7.6) | ||
| Low | 317 (31.9) | 141 (26.7) | 93 (38.6) | 83 (37.2) | ||
| Intermediate | 258 (26.0) | 146 (27.6) | 62 (25.7) | 50 (22.4) | ||
| High | 184 (18.5) | 104 (19.7) | 35 (14.5) | 45 (20.2) | ||
| Very high | 180 (18.1) | 119 (22.5) | 33 (13.7) | 28 (12.6) | ||
| Cytogenetic risk groups (IPSS-R) | ||||||
| Very good | 34 (3.4) | 14 (2.6) | 5 (2.1) | 15 (6.7) | ||
| Good | 609 (61.3) | 321 (60.7) | 153 (63.5) | 135 (60.5) | ||
| Intermediate | 165 (16.6) | 95 (18) | 42 (17.4) | 28 (12.6) | ||
| Poor | 72 (7.3) | 33 (6.2) | 17 (7.1) | 22 (9.9) | ||
| Very poor | 113 (11.4) | 66 (12.5) | 24 (10) | 23 (10.3) | ||
| Demographics | ||||||
| Age, median (years), IQR | 66 (58–73) |
66 (58–73) |
66 (58–73) |
67 (59–73) |
0.782 | 0.220 |
| Male, n (%) | 576 (58) | 285 (53.9) | 138 (57.3) | 153 (68.6) | 0.381 | 0.012 |
| Leukemic transformation, n (%) |
247 (24.9) |
145 (27.4) |
55 (22.8) |
47 (21.1) |
||
| Deaths, n (%) |
633 (63.7) |
359 (67.9) |
134 (55.6) |
140 (62.8) |
||
| Lost to follow-up, n (%) |
35 (3.5) |
20 (3.8) |
9 (3.7) |
6 (2.7) |
||
| Peripheral blood values | ||||||
| Haemoglobin, median (g/L), IQR |
95 (83–110) |
93 (82–109) |
99 (84–113) |
98 (85–112) |
0.018 | 0.79 |
| Neutrophil count, median (×109/L), IQR | 1.59 (0.82–2.66) |
1.12 (0.63–2.05) |
1.84 (1.20–2.66) |
2.54 (1.48–3.75) |
<0.001 | <0.001 |
| Lymphocyte count, median (×109/L), IQR |
1.21 (0.79–1.68) |
1.1 (0.70–1.54) |
1.26 (0.83–1.73) |
1.47 (0.99–2.05) |
0.006 | <0.001 |
| Platelet count, median (×109/L), IQR |
115 (58–232) |
97 (53–190) |
151 (74–266) |
128 (65–263) |
<0.001 | 0.227 |
| LDH | ||||||
| Data available, n (%) | 851 (85.7) | 461 (87.1) | 204 (84.6) | 186 (83.4) | ||
| LDH, median (U/L) | 199 (172–256) |
203 (170–257) |
198 (177–243) |
198 (172–268) |
0.798 | 0.917 |
| LDH > ULN (240 U/L), n (%) | 259 (26.1) | 149 (28.2) | 51 (16.2) | 59 (31.7) | 0.058 | 0.141 |
| Blasts | ||||||
| Blasts bone marrow, median (%), IQR | 3 (1–8) |
4 (2–10) |
2 (1–5) |
3 (1–7) |
<0.001 | 0.394 |
| Blasts peripheral blood, median (%), IQR Range |
0 (0–0) (0–19) |
0 (0–0) (0–19) |
0 (0–0) (0–18) |
0 (0–0) (0–19) |
0.484 | 0.382 |
| Bone marrow fibrosis | ||||||
| Data available, n (%) | 539 (54.3) | 299 (56.5) | 117 (48.5) | 123(55.2) | ||
| With fibrosis, n (%) | 75 (12.6) | 39 (13.0) | 19 (16.2) | 17 (13.8) | 0.398 | 0.600 |
| Transfusion dependent | ||||||
| Data available, n (%) | 415 (41.8) | 229 (43.7) | 94 (39) | 92 (41.3) | ||
| Transfusion dependent, n (%) | 218 (51.8) | 129 (56.3) | 45 (47.9) | 44 (47.8) | 0.166 | 0.995 |
MDS: myelodysplastic syndrome; SLD: single lineage dysplasia; MLD: multi-lineage dysplasia; RS: ringed sideroblasts; EB: excess blasts; MDS-U: myelodysplastic syndrome unclassifiable; IQR: inter-quartile range, LDH: lactate dehydroxygenase.